Ultrasmall Gold-Coated Mesoporous Polydopamine Nanoprobe to Enhance Chemodynamic Therapy by Self-Supplying H2O2 and Photothermal Stimulation
Source abstract
Abstract
Tumor microenvironment (TME) responsive chemodynamic therapy (CDT) showed an important application in inhibiting tumor growth by producing the highly toxic hydroxyl radical (·OH), but insufficient hydrogen peroxide (H2O2) and overexpressed glutathione (GSH) limited its application. Herein, by integrating photothermal therapy (PTT) and CDT, a new kind of mesoporous polydopamine (MPDA)-based cascade-reaction nanoplatform (MPDA@AuNPs-Cu) was designed for enhanced antitumor therapy, in which ultrasmall gold nanoparticles (AuNPs) with glucose oxidase (GOx)-like activity were deposited on MPDA for providing H2O2, and Cu2+ was chelated for GSH-responsive Fenton-like reaction. It was demonstrated that the MPDA@AuNPs-Cu nanoprobe showed high photothermal conversion efficiency and excellent biocompatibility. Moreover, the MPDA@AuNPs-Cu nanoprobe exhibited strong ·OH generation because of H2O2 self-generation and photothermal stimulation. Importantly, compared with MPDA-Cu, MPDA@AuNPs-Cu exhibited enhanced in vitro and in vivo CDT/PTT performance, by which the tumor growth was completely inhibited, achieving TME-responsive antitumor efficacy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of the Ministry of Education, Institute of Life Science and Green development, Chemical Biology Key Laboratory of Hebei Province, Hebei Key Laboratory of Precise Imaging of Inflammation Related Tumors, College of Chemistry & Environmental Science, Hebei University, Baoding 071002, P. R. China
Funding
Natural Science Foundation of Hebei Province · Hebei University · National Natural Science Foundation of China · Hebei Province
References (48)
Show source-provided references
1. 10.1039/D0BM00623H10.1039/D0BM00623H ↗
2. 10.1002/smll.20180185110.1002/smll.201801851 ↗
3. 10.1016/j.matt.2019.03.00710.1016/j.matt.2019.03.007 ↗
4. 10.1021/acsnano.8b0763510.1021/acsnano.8b07635 ↗
5. 10.1002/anie.20180566410.1002/anie.201805664 ↗
6. 10.1021/acs.chemrev.0c0097710.1021/acs.chemrev.0c00977 ↗
7. 10.1021/jacs.0c0560410.1021/jacs.0c05604 ↗
8. 10.1021/acsami.0c0701310.1021/acsami.0c07013 ↗
9. 10.1016/j.apmt.2020.10082710.1016/j.apmt.2020.100827 ↗
10. 10.1039/D1NR04196G10.1039/D1NR04196G ↗
11. 10.1002/adma.20190527110.1002/adma.201905271 ↗
12. 10.1016/j.biomaterials.2019.11937910.1016/j.biomaterials.2019.119379 ↗
13. 10.1016/j.jhazmat.2020.12256710.1016/j.jhazmat.2020.122567 ↗
14. 10.1002/anie.20151003110.1002/anie.201510031 ↗
15. 10.1039/C9CC06040E10.1039/C9CC06040E ↗
16. 10.1021/acsnano.0c0008210.1021/acsnano.0c00082 ↗
17. 10.1002/adfm.20211178410.1002/adfm.202111784 ↗
18. 10.1021/acsnano.1c0789310.1021/acsnano.1c07893 ↗
19. 10.1002/smll.20210742210.1002/smll.202107422 ↗
20. 10.1021/acsami.1c1219910.1021/acsami.1c12199 ↗
21. 10.1002/adfm.20190467810.1002/adfm.201904678 ↗
22. 10.1021/acsami.1c1034110.1021/acsami.1c10341 ↗
23. 10.1021/acsami.0c1521110.1021/acsami.0c15211 ↗
24. 10.1002/smll.20200089710.1002/smll.202000897 ↗
25. 10.1002/adma.20210601010.1002/adma.202106010 ↗
26. 10.1016/j.nantod.2021.10117410.1016/j.nantod.2021.101174 ↗
27. 10.1002/adma.20200689210.1002/adma.202006892 ↗
28. 10.1002/adfm.20190612810.1002/adfm.201906128 ↗
29. 10.1002/smll.20190389510.1002/smll.201903895 ↗
30. 10.1002/anie.20046044610.1002/anie.200460446 ↗
31. 10.1039/D1BM00015B10.1039/D1BM00015B ↗
32. 10.1002/smll.20220016510.1002/smll.202200165 ↗
33. 10.1002/adfm.20190771610.1002/adfm.201907716 ↗
34. 10.1016/j.biomaterials.2019.11940510.1016/j.biomaterials.2019.119405 ↗
35. 10.1016/j.colsurfb.2021.11159610.1016/j.colsurfb.2021.111596 ↗
36. 10.1021/acsami.7b0558310.1021/acsami.7b05583 ↗
37. 10.1016/j.ijpharm.2020.12002010.1016/j.ijpharm.2020.120020 ↗
38. 10.1039/D1NR03496K10.1039/D1NR03496K ↗
39. 10.1016/j.cej.2021.12945810.1016/j.cej.2021.129458 ↗
40. 10.1021/acsami.1c1261110.1021/acsami.1c12611 ↗
41. 10.1039/C9NR09236F10.1039/C9NR09236F ↗
42. 10.1039/C8NR01715H10.1039/C8NR01715H ↗
43. 10.1038/s42003-020-1016-z10.1038/s42003-020-1016-z ↗
44. 10.1021/acs.jpcc.5b0855810.1021/acs.jpcc.5b08558 ↗
45. 10.1002/smll.20200180510.1002/smll.202001805 ↗
46. 10.1016/j.cej.2020.12528010.1016/j.cej.2020.125280 ↗
47. 10.1002/adma.20170168310.1002/adma.201701683 ↗
48. 10.1016/j.cej.2022.13596410.1016/j.cej.2022.135964 ↗